KE, S., B, Y., L, S., RH, D., SL, W., HH, Z., . . . MS, S. (2017). Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. Dove Medical Press.
Chicago Style (17th ed.) CitationKE, Squires, Young B, Santiago L, Dretler RH, Walmsley SL, Zhao HH, Pakes GE, Ross LL, and Shaefer MS. Response by Gender of HIV-1-infected Subjects Treated with Abacavir/lamivudine Plus Atazanavir, with or Without Ritonavir, for 144 Weeks. Dove Medical Press, 2017.
MLA (8th ed.) CitationKE, Squires, et al. Response by Gender of HIV-1-infected Subjects Treated with Abacavir/lamivudine Plus Atazanavir, with or Without Ritonavir, for 144 Weeks. Dove Medical Press, 2017.
Warning: These citations may not always be 100% accurate.